Tcr2 Therapeutics: Rises on cancer therapy tie-up with CGT Catapult

TCR2 Therapeutics

26/03/2019 18:43

** Drug developer's shares  TCRR.O  up as much as 10 pct at
$18.43 
    ** Co says will work with Cell and Gene Therapy Catapult at
its manufacturing site in Stevenage in UK to make T-cell cancer
therapies  urn:newsml:reuters.com:*:nPn9FJrxQa
    ** Deal with CGT Catapult enables TCRR to meet its immediate
clinical trials needs - TCRR CEO Garry Menzel says 
    ** Having these advanced manufacturing facilities already in
place allows us to set up quickly and draw on the expertise and
support functions provided by CGT Catapult - TCRR 
    ** Including session gains, stock has risen nearly 19 pct
since its IPO last month 

 (Reporting by Manas Mishra in Bengaluru)
 ((Reuters Messaging:
manas.mishra.thomsonreuters.com@reuters.net))